Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

AstraZeneca’s Alexion adds to rare disease pipepline

Following its acquisition by drug giant AstraZeneca, New Haven-born Alexion Pharmaceuticals is growing its drug pipeline, agreeing to pay up to $500 million for New Jersey-based Caelum...

| By Kelley Gipson

Branford’s IsoPlexis makes Wall Street debut

IsoPlexis, a Branford-based life science technology company, went public in early October, with its stock initially trading at $15 a share. The company’s stock is listed...

| By Kelley Gipson

Yale Blavatnik Fund eyes digital health

A five-year-old Yale program that has helped dozens of drug and medical device companies get their ideas off the ground is now looking to help...

| By Kelley Gipson

UConn advances in Alzheimer’s and bone disease

UConn Associate Professor of Medicine Anne Delany has received a $2.2 million grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases to...

| By Kelley Gipson

Biorez awarded patents re BioBrace™ technology

Biorez reports four new patents relating to Biorez’s proprietary BioBrace™ Implant, which is a biocomposite soft tissue scaffold intended to reinforce soft tissue repair, and act as a...

| By Kelley Gipson

CT R&D tax credit best in U.S. — but only if …

By Bill Claffey, tax attorney and partner at the accounting firm Fiondella, Milone and LaSaracina LLP (FML) The Connecticut R&D tax credit allows corporations to...

| By Kelley Gipson

Precipio seeks more accurate cancer diagnoses

There’s a better way to do cancer diagnostics, says Precipio DiagnosticsCEO Ilan Danieli. He points a finger at existing methodologies that stress cost saving over accuracy. While...

| By Kelley Gipson

ReNetX focuses on spinal cord injury patients

ReNetX Bio’s NoGo Trap therapeutic has been given “fast track” status by the Food and Drug Administration. The firm’s mission statement is clear and precise:...

| By Kelley Gipson

Per Hellsund leads Cybrexa anti-tumor effort

As a co-founder of Cybrexa, Per Hellsund rejoined old colleagues Kevin Didden, Cybrexa board chair, and Kevin Rakin, a director. They are seeking to leverage research developed...